대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Rhabdomyolysis associated with fenofibrate leading to respiratory failure in a patient with diabetic chronic kidney disease
저자	Tae won LEE1, Ha NEE2, Yire KIM2, Hee jung PARK2, Eunjin BAE1, Hyun seop CHO2,3, Se-ho CHANG2,3, *Dong jun PARK1,3
출판정보	2017; 2017(1):
키워드	rhabdomyolysis, respiratory failure, fenofibrate, acutue kidney injury
초록	Case Study : Fenofibrate is frequently used to diabetic dyslipidemia and hypertriglyceridemia alone or in combination with statins. It rarely can cause rhabdomyolysis. However, there has been no report for rhabdomyolysis resulting in respiratory failure. We report rhabdomyolysis associated with fenofibrate therapy leading to respiratory failure in a patient with chronic kidney disease. A 64-year-old male patient with a medical history of type 2 diabetes mellitus, hypertension, and hyperlipidemia presented to the emergency department with progressive weakness. He had no recent viral diseases or other complaints. Four weeks before presentation he was started on 130 mg fenofibrate daily. Physical examination revealed markedly decreased motor power on both extremeties. Initial laboratory reports were as follows; CK 1671 U/L, LDH 1087 U/L, BUN 67.7 mg/dl, and Cr 4.43 mg/dl. Conservative managements including hydration and fenofibrate withdrawal were done. On admission 4th day, mechanical ventilator care was performed due to respiratory failure unexplained with laboratory and radiologic findings and cerebrospinal fluid analysis. CK increased to 7867 U/L and electromyography and nerve conduction study was compatible with toxic myopathy. In seven day, he was weaned off the ventilator. He was discharged from hospital on foot and followed up to outpatient without recurrence. Physicians have to bear in mind that fenofibrate can induce rhabdomyolysis leading to respiratory failure.
원문(PDF)	PDF 원문보기

목록

위로가기